

VENCLEXTA (venetoclax)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have **ONE** of the following:

- 1. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Mantle cell lymphoma (MCL)
 a. Patient has received at least ONE prior therapy
- 3. Relapsed or refractory acute myeloid leukemia (AML)
- 4. Newly-diagnosed acute myeloid leukemia (AML)

AND ALL of the following:

- a. 75 years or older **OR** have comorbidities that preclude use of intensive induction chemotherapy
- b. Used in combination with azacitidine **OR** decitabine **OR** low-dose cytarabine
- Waldenstrom macroglobulinemia (WM)
 a. Patient has received at least **ONE** prior therapy
- 6. Systemic light chain amyloidosis (SLCA)

AND ALL of the following for ALL indications:

- a. Prescriber agrees to monitor complete blood count (CBC) for neutropenia
- b. Prescriber agrees to advise female patients of childbearing potential to avoid pregnancy during treatment

Prior - Approval Limits

Duration 12 months

Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnoses

Federal Employee Program.

BlueCross. BlueShield

VENCLEXTA (venetoclax)

Patient must have the following:

- 1. Chronic lymphocytic leukemia (CLL)
- 2. Small lymphocytic lymphoma (SLL)
- 3. Mantle cell lymphoma (MCL)
- 4. Acute myeloid leukemia (AML)
- 5. Waldenstrom macroglobulinemia (WM)
- 6. Systemic light chain amyloidosis (SLCA)

AND ALL of the following for **ALL** indications:

- a. NO disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor complete blood count (CBC) for neutropenia
- c. Prescriber agrees to advise female patients of childbearing potential to avoid pregnancy during treatment

Prior - Approval Renewal Limits

Duration 24 months